Faecal volatiles in children with inflammatory bowel disease

  • Research type

    Research Study

  • Full title

    Evaluation of faecal volatile organic compounds in the diagnosis of paediatric inflammatory bowel disease

  • IRAS ID

    223199

  • Contact name

    Stephen J Allen

  • Contact email

    stephen.allen@lstmed.ac.uk

  • Sponsor organisation

    Alder Hey Children's NHS Foundation Trust

  • Duration of Study in the UK

    2 years, 4 months, 31 days

  • Research summary

    Inflammatory bowel disease (IBD) results in serious, lifelong gastrointestinal morbidity and poor quality of life. It has become much more common in children in recent years such that 25% of all new cases now occur in young people. Gastrointestinal endoscopy and imaging are required to confirm a diagnosis in children with suspected IBD. These investigations are highly distressing for children and their families, delay diagnosis and the start of treatment and are costly to the NHS. These tests need repeating at regular intervals further impairing quality of life. Children and families who have undergone these procedures voice a strong desire for tests that are non-invasive and give a rapid result. Parents of children with IBD are members of our research team and have helped to design the study.\n\nThe measurement of a marker of intestinal inflammation called “calprotectin” in a stool sample is helpful but does not differentiate IBD from other conditions such as gut infections. Stool volatile organic compounds (VOCs), responsible for stool odour, can be measured rapidly in the clinic at low cost. Research in adults by our group has shown that stool VOCs differentiated IBD from irritable bowel syndrome and also Crohn’s colitis from ulcerative colitis. However, early-onset IBD differs greatly from adult-onset disease; therefore, this new technology needs to be tested in children. \n\nAlthough stool VOCs have been shown to differentiate children with IBD from healthy controls, we plan to see if they can differentiate IBD from other common gut problems seen in paediatric clinics. We will also test whether VOCs can differentiate Crohn’s disease from ulcerative colitis in children and whether they are useful in monitoring response to treatment. Our ultimate goal is to see whether stool VOCs can replace endoscopy and imaging. This would greatly improve our patients’ experience and markedly reduce healthcare costs.

  • REC name

    North West - Preston Research Ethics Committee

  • REC reference

    17/NW/0333

  • Date of REC Opinion

    12 Jun 2017

  • REC opinion

    Further Information Favourable Opinion